AMRUTANJANNSEAmrutanjan Health Care Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Tue, 3 Feb, 2026 · 17:25 IST

Amrutanjan Health Care Q3 PAT at Rs 19.45 cr; declares second interim dividend of Re 1

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+10.0%Reaction day
₹580.00
prior close
₹593.20
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+8.7% vs market
Pharmaceuticals peers, median of 155sector+0.2%+9.8% vs sector

On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 9.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+2.2
10m
+1.6
15m
+1.0
30m
+0.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+10.0+1.3+8.7+0.2+9.8
Next day
+8.5+0.3+8.2-0.4+8.9
2d
+9.5-0.5+10.0-1.1+10.6
3d
+9.5+2.1+7.4+0.7+8.8
4d
+10.3+3.1+7.2+1.3+9.0
5d
+12.0+2.6+9.4+1.4+10.6
1w
+9.5+0.6+8.9+0.3+9.2
15d
+3.8-1.4+5.2-2.6+6.4
1m
-1.0-6.9+5.9-5.1+4.1
2m
-11.2-7.7-3.5-7.9-3.3
3m
-1.7+7.0-8.7+0.8-2.5
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amrutanjan Health Care reported Q3 FY26 revenue of Rs 141.04 cr, up about 15 percent from Rs 122.75 cr in Q3 FY25. Net profit was Rs 19.45 cr versus Rs 19.24 cr earlier. For 9 months FY26, revenue rose to Rs 352.78 cr from Rs 316.40 cr, with PAT up to Rs 41.73 cr from Rs 35.66 cr. Board declared a second interim dividend of Re 1 per share for FY26. Results include an exceptional charge of Rs 1.25 cr for new labour codes. Auditor issued an unmodified limited review report.

Likely market impact

Steady Q3 with double-digit revenue growth and a second interim dividend is positive for shareholders. Watch margin trends and follow-on labour code impact.